Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study

Hovenga, Sjoerd; Daenen, Simon M. G. J.; de Wolf, Joost T. M.; van Imhoff, Gustaaf W.; Kluin-Nelemans, Hanneke C.; Sluiter, Wim J.; Vellenga, Edo
May 2005
Annals of Hematology;May2005, Vol. 84 Issue 5, p311
Academic Journal
Thalidomide is an effective agent for patients with refractory multiple myeloma (MM) with a response rate of 30-40% at doses of 200-800 mg but with considerable side effects. We questioned whether lower doses of thalidomide in combination with a daily dose of cyclophosphamide might be an effective regimen with fewer side effects. We included 38 patients with relapsed or refractory MM. The median doses of thalidomide and cyclophosphamide were 100 and 95 mg/day, respectively. Side effects were observed in all patients, with neurotoxicity as the most troublesome. With a median follow-up of 14 months 84% of the patients responded, including 64% partial responses. The median time of progression-free survival was 30 months and the median overall survival time was 20 months. In conclusion, the results demonstrate that the combination of low-dose thalidomide with a daily dose of cyclophosphamide is an effective regimen with a high overall response rate and manageable side effects.


Related Articles

  • Thalidomide.  // Reactions Weekly;7/5/2008, Issue 1209, p30 

    The article describes the case of a 72-year-old man receiving thalidomide for multiple myeloma who developed pulmonary embolism. The patient had been receiving thalidomide 200 milligram (mg)/day, melphalan and dexamethasone for approximately 4 months before being admitted with dyspnoea and a dry...

  • Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma. Stöhr, Elisabeth; Schmeel, Frederic; Schmeel, Leonard; Hänel, Mathias; Schmidt-Wolf, Ingo // Journal of Cancer Research & Clinical Oncology;Dec2015, Vol. 141 Issue 12, p2205 

    Purpose: Treatment options for patients with relapsed and refractory multiple myeloma have improved since the introduction of immune-modulating agents such as lenalidomide and thalidomide. However, almost all patients relapse and suffer from an increasing amount of adverse events due to multiple...

  • Thalidomide.  // Reactions Weekly;4/1/2006, Issue 1095, p25 

    Presents a case of a 63-year-old woman who was hospitalised and started receiving thalidomide and dexamethasone for multiple myeloma. Medical history of the patient; Results of laboratory investigations; Medications given.

  • Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs. Kumar, S.; Raje, N.; Hideshima, T.; Ishitsuka, K.; Roccaro, A.; Shiraishi, N.; Hamasaki, M.; Yasui, H.; Munshi, N. C.; Richardson, P.; Figg, W. D.; Anderson, K. C. // Leukemia (08876924);Jul2005, Vol. 19 Issue 7, p1253 

    Thalidomide alone or in combination with steroids has significant activity in multiple myeloma (MM). However, given its teratogenic potential, analogs have been synthesized, retaining the anti-MM activity without these side effects. We examined the anti-MM activity of two thalidomide analogs,...

  • Emerging Treatment Options in the Management of Multiple Myeloma. Schlossman, Robert L. // Journal of Managed Care Medicine;2013, Vol. 16 Issue 1, p25 

    The article focuses on the concept of managing multiple myeloma with the onset of novel agents such as thalidomide, lenalidomide, and bortezomib. Since MM is not a curable disease yet, the researchers are combining these agents with or without the older agents to come up with an effective...

  • Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma. Alegre, Adrian; Vicua, Isabel; Aguado, Beatriz // Clinical Medicine Insights: Oncology;2012, Issue 6, p1 

    Lenalidomide is an oral immunomodulatory drug that has helped improve outcomes in multiple myeloma (MM) patients. Combination lenalidomide and dexamethasone (Len+Dex) has been shown to increase response rates and prolong survival compared with dexamethasone alone in patients with relapsed or...

  • Thalidomide.  // Reactions Weekly;3/15/2008, Issue 1193, p27 

    The article presents case reports of nine patients who developed arterial and venous thrombotic complications after receiving thalidomide for multiple myeloma. The patient characteristics are described including their sex, age, thrombosis onset and lesion type. All of them received oral...

  • Thalidomide.  // Reactions Weekly;3/14/2009, Issue 1243, p42 

    The article presents two case studies of women with multiple myeloma who developed hepatotoxicity while receiving thalidomide. The first patient started receiving 28-day cycles of thalidomide 50 mg/day and pulse dexamethasone with weekly thalidomide dosage increases of 50 mg/day to a maximum of...

  • Thalidomide.  // Reactions Weekly;4/11/2009, Issue 1247/1248, p33 

    The article describes the case of a 71-year-old man who developed pneumonitis following the administration of thalidomide for multiple myeloma. The patient became febrile 12 days after receiving thalidomide. Thalidomide and other antibacterial therapy were stopped and the patient's symptoms...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics